T2 Biosystems Announces Fourth Quarter and Full Year 2022 Financial Results
LEXINGTON, Mass., March 13, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial results for the fourth quarter and full year ended December 31, 2022.
Related news for (TTOO)
- T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
- T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor
- T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally
- T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
- T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens